Description
Dr. Giovannetti was invited to participate to the panel “Multidisciplinary clinical cancer research: where do we go from here?”, Chairs: E. Eisenhauer & M. Piccart at the Congress for the celebration of the EORTC 60th ANNIVERSARY on 30 September, 2022, Brussels (Belgium), bringing together EORTC members, partners, patient advocates and other key stakeholders in cancer research.
As Chair of the EORTC-PAMM group Dr. Giovannetti underlined the aim of this group at contributing to the several fields of Translational Research such as pharmacokinetics, pharmacogenomics, and studies on the molecular mechanisms of anticancer drug activity and on predictive biomarkers. EORTC has given essential contributions, such as in the CREATE trials assessing the activity and safety of crizotinib in different tumor types, who have specific molecular aberrations in the ALK or MET genes. Of note, these studies are also considered a landmark in the field of oncological studies for rare tumors, which typically need a multinational organization such as EORTC to be performed, and are very important because these tumors can provide information on specific biological pathways and treatments that can be translated to other tumor types in the future.
Furthemore, she explained that translation research has evolved over the years and it is predicted to further evolve exponentially due to digitalization, and big data. This is associated with some challenges including the need of a strong coordination between research and clinical teams
EORTC can play a critical role because it has the infrastructure, including the SPECTA platform (with appropriate biobank and database), and most importantly a multidisciplinary network of researchers and clinicians who are collaborating in order to integrate key biological questions into the trial design.
As Chair of the EORTC-PAMM group Dr. Giovannetti underlined the aim of this group at contributing to the several fields of Translational Research such as pharmacokinetics, pharmacogenomics, and studies on the molecular mechanisms of anticancer drug activity and on predictive biomarkers. EORTC has given essential contributions, such as in the CREATE trials assessing the activity and safety of crizotinib in different tumor types, who have specific molecular aberrations in the ALK or MET genes. Of note, these studies are also considered a landmark in the field of oncological studies for rare tumors, which typically need a multinational organization such as EORTC to be performed, and are very important because these tumors can provide information on specific biological pathways and treatments that can be translated to other tumor types in the future.
Furthemore, she explained that translation research has evolved over the years and it is predicted to further evolve exponentially due to digitalization, and big data. This is associated with some challenges including the need of a strong coordination between research and clinical teams
EORTC can play a critical role because it has the infrastructure, including the SPECTA platform (with appropriate biobank and database), and most importantly a multidisciplinary network of researchers and clinicians who are collaborating in order to integrate key biological questions into the trial design.
| Awarded date | 30 Oct 2022 |
|---|---|
| Degree of recognition | International |